Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| LL-37 (Cathelicidin) | Pentadeca Arginate (PDA) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 50-100 mcg daily via subcutaneous injection for immune support. | Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection. |
| Timing | Morning administration preferred for immune support. Topical application directly to wound sites. | Administer on an empty stomach. Inject near site of injury for localized effect. |
| Cycle Duration | 4-8 week cycles. Short-term use preferred due to limited long-term safety data. | 4-12 weeks depending on therapeutic target. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
LL-37 is a 37-residue amphipathic helical antimicrobial peptide, the only human cathelicidin, that kills bacteria by forming tetrameric channels that perforate cytoplasmic membranes. Beyond direct antimicrobial activity, it modulates innate immunity through formyl-peptide receptor 2 (FPR2), induces chemotaxis of neutrophils and monocytes, upregulates CXCR4 and IL-8, and neutralizes bacterial endotoxins (LPS). It also promotes wound healing through keratinocyte migration and angiogenesis.
Research indicates 50-100 mcg daily via subcutaneous injection for immune support.
Morning administration preferred for immune support. Topical application directly to wound sites.
4-8 week cycles. Short-term use preferred due to limited long-term safety data.
Pentadeca Arginate is a synthetic 15-amino acid peptide utilizing an arginate salt formulation of the BPC-157 sequence, designed to enhance nitric oxide production and promote angiogenesis. It stimulates collagen synthesis, enhances tissue repair through increased tensile strength, reduces inflammation via modulation of inflammatory cytokines, and accelerates cellular proliferation in tendon fibroblasts. The arginate salt form provides superior stability and bioavailability compared to traditional acetate formulations.
Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.
Administer on an empty stomach. Inject near site of injury for localized effect.
4-12 weeks depending on therapeutic target.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →